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Abstract
Background Respiratory syncytial virus (RSV) causes seasonal respiratory infection with potentially serious
complications in children, and leads to hospitalization rates as high as 50% in high-risk infants. Safe
and effective immunoprophylaxis (palivizumab) is available, but costly. The American Academy of
Pediatrics (AAP) recommends palivizumab only for infants at high risk of complications, and only
during the RSV season. Although the current AAP guidelines acknowledge the existence of spatial
and temporal variation in RSV incidence, they do not recommend spatial or temporal adjustments to
immunoprophylaxis regimen outside of Florida. In this study, we investigate the value of using spatial
and temporal variation in RSV incidence to adjust the RSV prophylaxis regimen in Connecticut.
Methods We describe a generalized additive model of RSV incidence using cubic cyclic penalized splines and
apply that model to hospital admissions in Connecticut between July 1995 and June 2013. We use
the model to estimate the fraction of all RSV cases in Connecticut occurring while immunoprophylaxis
(administered according to the AAP guidelines) offers protection from RSV infection (“preventable
fraction”). We also formulate several alternative immunoprophylaxis regimens, with the same net
pharmaceutical cost as the AAP-recommended regimen, and similarly estimate their preventable
fraction.
Results Using preventable fraction to assess different immunoprophylaxis regimens, we found that reg-
imens adjusted for county-level variation in timing of RSV seasons are superior to the current
AAP-recommended regimen. We also considered the effect of rounding the timing of the first dose
of prophylaxis to pragmatic calendrical boundaries (weekly, biweekly, and monthly), and found
that benefits of alternative regimens over the AAP-recommended regimen persisted with biweekly
rounding, but not with monthly rounding. Our best-performing pragmatic alternative to the AAP
guidelines was based on the regional RSV season midpoint with biweekly rounding. In comparison
to the AAP recommendation, whose preventable fraction is 94.08% (95% CI: 93.71 – 94.42%), that
alternative yielded improvement to preventable fraction of 95.07% (95% CI: 94.74 – 95.36%). We
also found that alternative regimens adjusted for annual variation in RSV season are non-superior to
spatially adjusted regimens.
Conclusion Overall, we recommend county-level spatial analysis of RSV incidence as the starting point for
RSV immunoprophylaxis optimization in Connecticut. However, the potential reduction in RSV
hospitalizations should be weighed against the potential increase in implementation cost.
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1 Introduction
Respiratory syncytial virus
Respiratory syncytial virus (RSV) causes upper respira-
tory infections in humans of all ages. In adults, RSV
infection is typically asymptomatic or gives rise to mild
respiratory illness. However, RSV infection often incites
more serious respiratory illness in children, with hospi-
talization rates as high as 4.4% in infants with no comor-
bidities, making RSV a leading cause of hospitalization
among infants.1–4
For infants, risk factors of serious illness and hospital-
ization due to RSV infection include prematurity, chronic
lung disease of prematurity, congenital heart disease,
anatomic pulmonary abnormalities, neuromuscular dis-
orders, trisomy 21, and immunocompromised status.5
Hospitalization rate due to RSV among high-risk infants
is anywhere from two to ten times higher than among
infants with no comorbidities.4
RSV immunoprophylaxis
Immunoprophylaxis with palivizumab, a monoclonal an-
tibody medication, has been approved in the US for pre-
vention of RSV infection since 1998. Palivizumab is ad-
ministered via intramuscular injection and requires five
monthly doses, priced at $1500-$3000 per dose.6,7
Palivizumab has been found to be effective in reduc-
ing hospitalizations due to RSV; in double-blinded trials
in high-risk infants, it reduced hospitalization rate by
45-55% compared to placebo.8,9 Its has also been found
to be safe and well-tolerated in clinical trials.8
Owing to the high cost, the American Academy of
Pediatrics (AAP) guidelines, revised in 2014, recommend
palivizumab immunoprophylaxis only for high-risk in-
fants, and only during RSV season.5,10,11
RSV seasonality
RSV seasonality has been established throughout the
United States, based on National Respiratory and En-
teric Virus Surveillance System data. In all states except
for Florida, it shows a stable season onset between mid-
November and early January and a stable season offset
between mid-March and late April.12,13 RSV season in
Florida begins approximately two months earlier than in
other states.13
The AAP acknowledges the potential significance of
spatial and temporal variation in RSV incidence, but —
outside of Florida — does not recommend local variance
from nation-wide prophylaxis guidelines.5
Spatio-temporal variability of RSV
Nationwide spatial variability of RSV season has been
established by the Centers for Disease Control and Pre-
vention (CDC).12,13
In Connecticut, the Department of Public Health (CT
DPH), via its Office of Health Care Access (OHCA), main-
tains a database of all hospitalizations in every non-
federal short-stay acute-care general hospital in the state.
Previous analysis of this database at the Yale University
School of Public Health has shown regional variability
in time of peak RSV incidence within Connecticut.14 No
prior research is available regarding year-to-year varia-
tion in timing of RSV season in Connecticut.
Study aims
Motivated by the AAP’s recognition of the significance of
spatial variation in formulating prophylaxis guidelines,
and the known spatial variability of RSV incidence in
Connecticut, we aim to determine whether spatial and
temporal variability can be used to optimize RSV pro-
phylaxis in Connecticut by asking these questions:
• To what extent does regional variability of RSV
incidence in Connecticut impact the effectiveness
of the AAP-recommended prophylaxis regimen?
• Can we use spatial analysis of RSV to propose al-
ternative regimens that would increase the ben-
efits of prophylaxis in comparison to the AAP-
recommended regimen, without increasing the to-
tal cost of the prophylactics the regimen?
• Is there year-to-year variation in timing of RSV
season in Connecticut?
• Can we take advantage of any year-to-year varia-
tion to improve upon AAP-recommended prophy-
laxis, without increasing treatment cost?
The study was approved by the Human Investiga-
tion Committees at Yale University and the CT DPH. The
authors assume full responsibility for analyses and inter-
pretation of the data obtained from CT DPH.
2 Methods
Case definition
We defined an RSV-associated hospitalization in Con-
necticut to be a hospital stay for which:
• the postal code of residence listed in patient’s med-
ical record was in Connecticut*, and
• the hospital stay was associated with ICD-9-CM
diagnosis code 079.6 (RSV), 466.11 (Acute bron-
chiolitis due to RSV), or 480.1 (Pneumonia due to
RSV).
Using the OHCA weekly hospitalization statistics, we
identified 318660 RSV-associated hospitalizations in Con-
necticut between July 1995 and June 2013 (inclusive).
*According to the zipcode → state mapping in R zipcode package version 1.0
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Data normalization
Given that RSV seasons peak early in each calendar year,
we assigned to each surveillance year 12 months of data
starting in July of previous year. OHCA provided us with
hospitalization records aggregated into Monday-Sunday
calendar weeks; we assigned the first full calendar week
of July to be surveillance week 1 in each surveillance
year.
Due to changes in diagnostic coding, we excluded
data prior to July 1996; we similarly excluded data start-
ing after June 2013, due to incompleteness.
Choice of model
Our goal was to construct a model of annual RSV inci-
dence that allowed us to easily estimate complex charac-
teristics of RSV seasons, such as season onset and offset.
To that end, we looked for a model that allowed easy sam-
pling of estimated model parameters; coupling this with
Monte Carlo sampling — after transforming model pa-
rameters into response variables — allowed us to sample
arbitrary response variables.
We were willing to assume that RSV incidence is the
result of a Poisson process whose log can be modeled as a
piecewise twice-differentiable function of time. To meet
those criteria and assumptions, we chose a log-linked
generalized additive model (GAM) with penalized cubic
B-splines for our analysis.
We developed a custom R package for estimation
of arbitrary characteristics of infectious disease out-
breaks (as long as the outbreaks are amenable to GAM);
this package is available at github.com/airbornemint/
outbreak-inference.
Spatial aggregation of RSV incidence
For our spatial analysis, we aggregated RSV incidence
data between 1995 and 2013 into five regions:
• One region for the entire state
• One region for each of the counties with high RSV
case counts: Hartford County, Fairfield County, and
New Haven County (Figure 1).
• One discontiguous region comprised of all remain-
ing counties in Connecticut: Tolland, Windham,
Middlesex, Litchfield, and New London (“low-RSV
counties”).
We chose county-level aggregation with an eye to-
wards using this data to inform clinical practice guide-
lines, which are typically based on administrative regions
for reasons of administrative and implementation sim-
plicity.
We chose to aggregate low-RSV counties into a single
region because our analysis in those counties individu-








Average RSV cases per year <50 >100
Figure 1: Subdivision of Connecticut into high-RSV and low-RSV
counties
Evaluating the AAP prophylaxis recommenda-
tion
We began by assessing the current AAP RSV prophylaxis
guidelines. These guidelines recommend RSV prophy-
laxis with 5 monthly doses of palivizumab, starting in
November, for all high-risk infants in their first year of
life; in the second year of life, only some subgroups are
recommended to receive palivizumab.
For simplicity, we assumed that protection by
palivizumab begins on November 15th and lasts 24
weeks.
We defined the fraction of all RSV cases that is pre-
ventable by a prophylaxis regimen (“preventable frac-
tion”) to be the ratio of
• the number of RSV-associated hospitalizations that
occur while the prophylaxis regimen offers protec-
tion to those who receive prophylaxis as scheduled,
and
• the total number of RSV-associated hospitaliza-
tions.
Given that high-risk infants are a small subgroup of
the general population, we assumed that our model of
RSV hospitalizations among all infants is an unbiased
approximation of RSV hospitalizations among high-risk
infants, and that, therefore, the preventable fraction of a
prophylactic regimen is an unbiased estimate of the frac-
tion of high-risk infants who benefit from prophylaxis.
Estimating all-years characteristics of RSV
seasons
We then turned our attention to spatial variation of sea-
sonal RSV patterns between July 1995 and June 2013.
In particular, we defined season onset as the time when
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cumulative incidence rises beyond 2.5% of the total cu-
mulative incidence, and season offset as the time when
cumulative incidence rises beyond 97.5% of the total
cumulative incidence. We aggregated our data by surveil-
lance week across all surveillance years, and estimated
RSV season onset and offset for each region.
The choice of 2.5% and 97.5% incidence thresholds
was based on our intent to use estimates of RSV season
onset and offset to put forth alternative prophylaxis regi-
mens (as described below), while maintaining 5-month
dosing schedule (and therefore not increasing medica-
tion cost). Incidence cutoffs other than 2.5% and 97.5%
were briefly investigated, but quickly ruled out because
they produced prophylaxis regimens starting long prior
to RSV season onset or ending long after RSV season
offset, and therefore had very low preventable fractions.
Evaluating spatially adjusted prophylaxis regi-
mens
Following this analysis, we estimated the regional and
statewide preventable fraction for six spatially adjusted
prophylaxis regimens:
• By statewide all-years onset: prophylaxis admin-
istration begins at statewide all-years median RSV
season onset.
• By statewide all-years midpoint: prophylaxis ad-
ministration begins 12 weeks before the average
of the (statewide all-years median) season onset
and offset.
• By statewide all-years offset: prophylaxis admin-
istration begins 24 weeks before the (statewide
all-years median) RSV season offset.
• By regional all-years onset: prophylaxis admin-
istration begins at regional† all-years median RSV
season onset.
• By regional all-years midpoint: prophylaxis ad-
ministration begins 12 weeks before the average of
the (regional all-years median) RSV season onset
and offset.
• By regional all-years offset: prophylaxis admin-
istration begins 24 weeks before the (regional all-
years median) RSV season offset.
In all our alternative regimens, prophylaxis consists
of five monthly doses of palivizumab, and protection is
assumed to last 24 weeks from the first dose.
Accommodating implementation complexity
Keeping in mind implementation constraints of clinical
practice guidelines, we performed three additional vari-
ants of our spatial analysis:
• Weekly rounding: prophylaxis start and end date
rounded to the nearest calendar week,
• Biweekly rounding: prophylaxis start and end
date rounded to the nearest two-week calendar
period, with periods chosen to approximately align
with November 15th, and
• Monthly rounding: prophylaxis start and end
date rounded to the nearest four-week calendar pe-
riods, with periods chosen to approximately align
with November 15th.
In each variant, we again estimated the preventable
fraction of all six spatially adjusted regimens.
Temporal aggregation of RSV incidence
Our analysis thus far assumed that RSV seasons are sim-
ilar year-to-year. To analyze the effects of year-to-year
variation between RSV seasons on prophylaxis regimens,
we chose to aggregate our data into (overlapping) peri-
ods of three consecutive years — in order to maintain a
higher level of statistical power, as well as to limit impact
of short-term variation on our results.
This gave us 17 three-year periods, with the 1997
period covering surveillance years 1995 through 1997,
and the 2013 period covering 2011 through 2013.
We began our temporal analysis by estimating onset
and offset for each three-year period, using the same
penalized spline GAM as all-years analysis, producing —
as before — statewide and regional estimates of 2.5%
onset and 97.5% offset.
To evaluate year-to-year variation in RSV season on-
set and offset we modeled median RSV three-year onset
and offset against time using simple linear regression.
We did not analyze any other long-term patterns,
such as cyclicity.
Evaluating alternative recent-years prophy-
laxis regimens
Finally, to assess the impact of any long-term trends in
RSV season timing on prophylaxis, we evaluated three
additional prophylaxis regimens. Here, each prophylaxis
regimen is adjusted annually based on RSV data from
the preceding three-year period:
• By statewide recent-years onset: prophylaxis ad-
ministration in a given year begins at statewide
median onset from the preceding three years.
• By statewide recent-years midpoint: prophy-
laxis administration begins 12 weeks before the
average of the (statewide median) onset and offset
from the preceding three years.
• By statewide recent-years offset: prophylaxis ad-
ministration in a given year begins 24 weeks before
the (statewide median) offset from the preceding
three years.
†county-wide, or — in the case of low-RSV counties — low-RSV-region-wide
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Figure 2: Regional variation in RSV season onset and offset in
Connecticut
We then compared those regimens to the one recom-
mended by AAP and to the six spatially adjusted alterna-
tives (with no calendrical rounding) discussed above.
As before, these alternative regimens involved five
monthly doses of palivizumab giving 24 weeks of protec-
tion.
3 Results
RSV season timing varies regionally
Compared to the statewide median onset of RSV season
at 17.25 weeks (95% CI: 16.85 – 17.60 weeks) and off-
set at 41.30 weeks (95% CI: 40.95 – 41.65 weeks), RSV
season in Fairfield county has earlier median onset at
16.05 weeks (95% CI: 15.20 – 16.75 weeks) and later









































Figure 3: Regional variation in the fraction of RSV hospitaliza-
tions occurring while protection by palivizumab — ad-
ministered per the AAP guidelines — is active
Meanwhile, in comparison with the statewide RSV
season onset and offset, the low-RSV region has RSV
season with later onset at 19.65 weeks (95% CI: 16.85 –
17.60 weeks); season offset shows no change from the
statewide median (Figure 2).
The AAP guidelines perform best in low-RSV coun-
ties and worst in Fairfield county
Statewide, our model shows that 94.08% of RSV cases
(95% CI: 93.71 – 94.42%) occur while palivizumab, ad-
ministered per the AAP guidelines, offers protection.
The AAP guidelines perform better in the low-RSV
counties, where 96.63% cases (95% CI: 96.01 – 97.17%)
occur during the prophylaxis interval, but worse in Fair-
field county, where 91.90% cases (95% CI: 91.05 –
92.70%) occur during this time (Figure 3).


























































































































AAP-recommended prophylaxis RSV season
Figure 4: Regional variation in the relative timing of the RSV season in Connecticut and the AAP-recommended prophylaxis regimen,
showing the gap between season onset and prophylaxis start date, notable particularly in Fairfield county
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Figure 5: Comparison of six spatially adjusted RSV prophylaxis regimens to the AAP-recommended regimen, showing statewide
superiority and regional non-inferiority of spatially adjusted regimens. Preventable fraction: the fraction of all RSV-associated
hospitalizations occurring while the prophylaxis regimen provides protection
This is caused by temporal misalignment between
the RSV season (delineated by median 2.5% onset and
97.5% offset in each region), and the timing of the AAP-
recommended prophylaxis regimen (Figure 4). Fairfield
county, owing to its early season onset, sees dispropor-
tionately many cases before prophylaxis administration
begins; on the other hand, the low-RSV counties, ow-
ing to their late season onset and relatively shorter RSV
seasons, see almost all of their RSV cases within the
prophylaxis window.
Spatially adjusted regimens are superior to the AAP
recommendations
Based on all-years data, the six spatially adjusted prophy-
laxis regimens (with no rounding of prophylaxis dates),
when compared to the AAP guidelines, yield non-inferior
results in all regions, and superior results statewide (Fig-
ure 5).
Statewide, the AAP guidelines offer protection to
94.08% cases (95% CI: 93.71 – 94.42%). The alternative
regimen based on all-years statewide onset yields the
smallest increase, to 94.97% (95% CI: 94.64 – 95.28%);
other alternative regimens yield similar results.
Most of the increase comes from Hartford county,
where the AAP guidelines protect 93.67% of cases (95%
CI: 92.77 – 94.46%), whereas the alternative regimen
based on all-years regional offset generates the smallest
increase, to 95.05% (95% CI: 94.43 – 95.84%); other
alternative regimens are comparable.
In every region, all alternative regimens based on
all-years analysis are non-inferior to the AAP guidelines
and non-superior to each other.
Calendrical rounding rapidly erases gains over the
AAP-recommended regimen
After we applied weekly, biweekly, and monthly rounding
to start and end dates of our six alternative immunopro-
phylaxis regimens, we found that longer rounding in-
tervals diminished the benefit of spatial analysis (Figure
6).
With weekly rounding, our regimens were non-
inferior to the AAP recommendation, and produced an
increase in preventable fraction from AAP’s 94.08% (95%
CI: 93.71 – 94.42%) to 94.98% (95%CI: 94.65 – 95.30%)
statewide.
Biweekly rounding yielded regimens similarly non-
inferior to the AAP recommendation, with an increase in
preventable fraction to 95.07% (95%CI: 94.74 – 95.36%)
statewide.
However, with monthly rounding, the gains almost
completely vanished, with preventable fraction not ex-
ceeding 94.54% (95% CI: 94.19 – 94.87%). Further-
more, all our regimens with monthly rounding were non-
superior to the AAP-recommended regimen in all regions.
Page 11 of 14



























Figure 6: The effect of calendrical rounding of start and end of spatially adjusted RSV prophylaxis regimens on their performance,
showing that longer rounding intervals diminish the benefits of alternative regimens over the AAP-recommended regimen.
Preventable fraction: the fraction of all RSV hospitalizations occurring while the prophylaxis regimen offers protection
RSV season onset is slowly moving earlier
Our linear regression of median RSV season onset and
offset over three-year periods indicates that season onset
has slowly been drifting earlier (Figure 7), at a rate of
-1.04 days/year (95% CI: -2.03 – -0.06 days/year). It is
unclear whether this is a part of a larger pattern, such
as a cycle spanning decades.
Season offset, on the other hand, has not been drift-






















Figure 7: Annual variability in RSV season onset and offset in
Connecticut
Temporally-adjusted prophylaxis regimens are non-
superior to others
Compared to our regional all-years analysis, the three reg-
imens based on statewide recent-years analysis produced
non-superior results everywhere, and inferior results in
the low-RSV counties (Figure 8).
Due to the non-superiority of regimens based on
statewide recent-years analysis, we did not evaluate reg-
imens based on regional recent-years data.
4 Discussion
Conclusions
Our analysis confirms the existence of regional variation
of RSV season timing in Connecticut (defined by RSV
season onset and offset) observable at the county level.
We have also shown a misalignment between the pro-
phylaxis schedule recommended by the AAP and the tim-
ing of the RSV season throughout Connecticut, with most
counties’ RSV season starting before protection from the
first dose of prophylaxis takes hold, and ending before
protection from the last dose wanes. This misalignment
is particularly notable in Fairfield County, due to its early
season onset.
Our effort to optimize timing of the prophylaxis reg-
imen (without changing its duration, and therefore its
pharmaceutical cost) shows the possibility of a theoret-
ical 1-2% statewide decrease in RSV-associated hospi-
talizations among high-risk infants each year, primarily
in counties with higher RSV burden (Fairfield, Hartford,
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Figure 8: Comparison of prophylaxis regimens based on all-years data to those based on recent-years data, showing temporal analysis
adds no benefit over spatial analysis alone. Preventable fraction: fraction of RSV hospitalizations occurring while the
prophylaxis regimen offers protection
and New Haven counties).
The magnitude of that improvement wanes upon en-
countering practicalities of clinical practice guideline im-
plementation. Nonetheless, with clinical practice guide-
lines localized at the county level, and the timing of
prophylaxis adjusted in each county by less than a whole
month from the current AAP guidelines, we still found the
potential for ∼1% statewide decrease in RSV-associated
hospitalizations among high risk infants.
The prophylaxis regimen with which we were able
to attain this improvement is the one in which prophy-
laxis in each county is timed relative to the midpoint of
the RSV season (rounded to two weeks) in that county,
which simultaneously reduces unprotected cases early in
the season and ineffective prophylaxis late in the season.
Increasing complexity of practice guidelines carries
with it increased cost of implementation, such as training
of clinicians and other healthcare workers. It is therefore
not apparent from our research alone that the potential
benefits would outweigh the costs.
Although we found a weak statewide trend in RSV
season onset becoming earlier over time, further analysis
did not yield any improvements to prophylaxis based
on that trend. Since temporal variation in clinical guide-
lines would lead to a higher implementation burden than
spatial variation, we see no reason to base RSV immuno-
prophylaxis clinical practice guidelines on temporal vari-
ation in RSV season timing.
Limitations
Although we were able to reach some conclusions about
the impact of calendrical rounding on spatially adjusted
prophylaxis regimens, ultimately our analysis is ham-
strung by weekly aggregation of hospital admission data.
To properly propose and evaluate any fine-tuning to RSV
prophylaxis guidelines, we recommend use of daily data.
Throughout, we assumed that RSV-associated hospi-
talizations are an unbiased estimate of RSV incidence
in the general population; in doing so, we implicitly
assumed that infectiousness and virulence of RSV are
constant over time, for which we have no verification.
Our model of palivizumab immunoprophylaxis as-
sumes a protection period with a hard start at administra-
tion and a hard stop at 24 weeks post-administration; the
physiologic response to monoclonal antibody immuno-
prophylaxis is actually tapered on both ends.
Similarly, we assumed the protection by palivizumab
is constant at 100% throughout the protection period;
however, not only is breakthrough RSV illness known to
occur in patients on palivizumab, but it is an indication
for discontinuing the prophylaxis regimen.
In areas of Connecticut associated with a relatively
high amount of interstate travel (such as urban centers
near the state lines), our analysis — by only considering
residents of Connecticut — likely underestimates RSV
burden.
Finally, towns that see substantial inter-county travel
(for example, employment hubs near county lines) likely
bias our regional analysis.
Page 13 of 14
Assessment and optimization of RSV prophylaxis regimens in Connecticut, 1995-2013
Bibliography
1. Hall, CB, Weinberg, GA, Iwane, MK, et al. The burden of respiratory syncytial virus infection in young children.
The New England Journal of Medicine 2009;360:588–598. doi: 10.1056/NEJMoa0804877.
2. Hall, CB, Weinberg, GA, Blumkin, AK, et al. Respiratory syncytial virus-associated hospitalizations among
children less than 24 months of age. Pediatrics 2013;132:e341–8. doi: 10.1542/peds.2013-0303.
3. Zhou, H, Thompson, WW, Viboud, CG, et al. Hospitalizations associated with influenza and respiratory syncytial
virus in the United States, 1993-2008. Clinical Infectious Diseases 2012;54:1427–1436. doi: 10.1093/cid/
cis211.
4. Boyce, TG, Mellen, BG, Mitchel, EF, Wright, PF, and Griffin, MR. Rates of hospitalization for respiratory syncytial
virus infection among children in Medicaid. The Journal of Pediatrics 2000;137:865–870. doi: 10.1067/mpd.
2000.110531.
5. American Academy of Pediatrics Committee on Infectious Diseases and American Academy of Pediatrics Bronchi-
olitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children
at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:e620–38. doi:
10.1542/peds.2014-1666.
6. Hampp, C, Kauf, TL, Saidi, AS, and Winterstein, AG. Cost-effectiveness of respiratory syncytial virus prophy-
laxis in various indications. Archives of Pediatrics & Adolescent Medicine 2011;165:498–505. doi: 10.1001/
archpediatrics.2010.298.
7. Andabaka, T, Nickerson, JW, Rojas-Reyes, MX, Rueda, JD, Bacic Vrca, V, and Barsic, B. Monoclonal antibody
for reducing the risk of respiratory syncytial virus infection in children. The Cochrane Database of Systematic
Reviews 2013;28:CD006602. doi: 10.1002/14651858.CD006602.pub4.
8. Group, TI-RS. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization
from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–537. doi: 10.1542/peds.
102.3.531.
9. Feltes, TF, Cabalka, AK, Meissner, HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory
syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of
Pediatrics 2003;143:532–540. doi: 10.1067/S0022-3476(03)00454-2.
10. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use
of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and
Newborn. 1998.
11. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for
the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442–1446.
12. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus–United States, July 2007-June
2011. MMWR. Morbidity and Mortality Weekly Report 2011;60:1203–1206.
13. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus activity–United States, July
2011-January 2013. MMWR. Morbidity and Mortality Weekly Report 2013;62:141–144.
14. Noveroske, DB. Respiratory syncytial virus in Connecticut: Predictors of seasonal epidemic timing. Public Health
Theses 2016.
Page 14 of 14
